Table 1.
The median levels of Anti–SARS-CoV-2 anti-RBD and neutralising antibodies in the first 12 weeks following the second dose of the BNT162b2 mRNA vaccine.
| Week 1 | Week 2 | Week 3 | Week 4 | Week 8 | Week 12* | ||
|---|---|---|---|---|---|---|---|
| Anti-S RBD Ab (U/mL) | Total (n = 71) |
3898.0 (2107.5–5478.5) |
2432.0† (1742.5–3927.0) |
2152.0† (1288.0–3894.5) |
1753.0† (1053.5–2834.5) |
1245.0† (794.4–2036.0) |
1163.0 (683.4–1743.0) |
| Male (n = 32) |
3961.5 (2095.0–5706.0) |
2685.5 (1747.8–4221.5) |
2442.0 (1271.8–4268.8) |
1967.0 (1037.0–2756.0) |
1371.5 (814.5–1974.8) |
1304.5 (791.4–1709.8) |
|
| Female§ (n = 39) |
3817.0 (2342.0–5107.0) |
2378.0 (1866.5–3522.5) |
2135.0 (1351.5–3571.5) |
1619.0 (1128.0–2817.5) |
1192.0 (794.4–2118.5) |
919.4 (644.0–1720.5) |
|
| 20 s (n = 25) |
3968.0 (2099.0–5465.0) |
2760.0 (1818.0–3860.0) |
2152.0 (1262.0–3794.0) |
2017.0 (1040.0–3282.0) |
1503.0 (842.9–2362.0) |
1300.0 (734.7–1913.0) |
|
| 30 s (n = 26) |
3954.0 (2443.2–4822.5) |
2539.5 (1956.5–3959.0) |
2205.5 (1527.5–3618.5) |
1826.0 (1217.2–2434.8) |
1305.0 (905.1–1932.8) |
1194.0 (769.5–1625.8) |
|
| 40 s (n = 20) |
3610.5 (2038.2–5706.0) |
2277.5 (1693.5–3796.8) |
1892.5 (1286.8–4206.8) |
1570.5 (935.9–2609.5) |
1054.0 (539.2–1792.5) |
801.7 (465.6–1297.2) |
|
| Neutralising Ab (Inhibition %) | Total (n = 71) |
97.54 (96.85–97.81) |
96.93† (96.33–97.15) |
96.82† (96.06–97.15) |
96.87 (96.20–97.13) |
96.31† (93.89–97.33) |
94.87† (89.24–96.99) |
| Male (n = 32) |
97.46 (96.60–97.83) |
96.87 (96.34–97.15) |
96.74 (95.95–97.15) |
96.70 (96.08–97.11) |
96.41 (94.06–97.29) |
95.64 (90.42–97.00) |
|
| Female (n = 39) |
97.54 (97.08–97.79) |
96.97 (96.36–97.23) |
96.87 (96.25–97.17) |
96.92 (96.28–97.13) |
96.14 (93.72–97.33) |
94.62 (88.52–96.95) |
|
| 20 s (n = 25) |
97.54 (97.26–97.79) |
96.93 (96.59–97.09) |
96.82 (96.47–97.15) |
96.93 (96.30–97.18) |
96.77 (94.58–97.48) |
96.09 (91.07–97.60) |
|
| 30 s (n = 26) |
97.61 (96.90–97.90) |
96.95 (96.30–97.19) |
96.95 (96.19–97.19) |
96.90 (96.46–97.12) |
96.64 (94.19–97.30) |
95.64 (89.63–97.11) |
|
| 40 s (n = 20) |
97.46 (96.51–97.73) |
96.87 (96.21–97.11) |
96.69 (95.49–97.02) |
96.73 (95.27–97.00) |
95.78 (90.17–96.90) |
93.39 (84.49–96.02) |
|
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RBD, receptor binding domain of viral spike protein.
* Two participants were loss, so total number of participants were 69. †p < 0.01.